國家衛生研究院 NHRI:Item 3990099045/11623

NHRI > Institute of Biotechnology and Pharmaceutical Research > Hung-Jung Wang > Conference Papers/Meeting Abstract > Item 3990099045/11623

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11623

Title:	Identification of the PCa28 gene signature as a predictor in prostate cancer
Other Titles:	IEEE International Conference on Bioinformatics and Bioengineering
Authors:	Lee, JY;Lin, SY;Chuang, YH;Huang, SH;Tseng, YY;Yang, JM;Lin, CY;Wang, HJ;Ieee
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	Prostate cancer (PCa) is the second-leading cause of cancer death among men in the worldwide. Most PCa is slowly growing and usually early symptomless. About 70% of PCa patients were diagnosed at later stage and metastasis has been observed. Additionally, the cure rate of PCa closely relies on the early diagnosis with biomarkers. Prostatic Specific Antigen (PSA) is currently the only clinical biomarker for PCa diagnosis. However, the PSA test has inherent limitations and has about 75% of false-positive results. The identification of a set of genes (as biomarkers) for diagnosis and prognosis is an urgent clinical issue for PCa. Here, we integrated genome-wide analysis and protein-protein interaction network to identify potential genes for early diagnostic biomarkers of PCa. First, we collected gene expression datasets of 145 PCa samples, consisting of both tumor and corresponding normal tissues, from two different sources in Gene Expression Omnibus (GEO). We found 158 and 268 significantly highly and lowly expressed genes, respectively, in tumor samples. Moreover, we proposed cluster score (CS) and predicting score (PS) to select 28 prostate cancer-related genes (called PCa28). The results indicate that PCa28 can discriminate between the normal/tumor tissues and are specific for prostate cancer. Finally, we examined 8 genes in PCa28 on four PCa cell lines by real time quantitative polymerase chain reaction (RT-qPCR). Experimental results show that up-regulated genes have higher expression level in tumor cells in comparison to normal cells, and down-regulated genes have lower expression level in tumor cells. We believe that our method is useful and PCa28 are potential biomarkers that provide the clues to develop targeting therapy for PCa.
Date:	2018-10
Relation:	Proceedings 2018 Ieee 18th International Conference on Bioinformatics and Bioengineering. 2018 Oct:155-158.
Link to:	http://dx.doi.org/10.1109/bibe.2018.00037
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000455225600029
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85060368468
Appears in Collections:	[Hung-Jung Wang] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000455225600029.pdf		342Kb	Adobe PDF	119	View/Open

Loading...